Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease.

Thomas P Chapman Catarina Geraldes de Frias GomesEdouard LouisJean-Frédéric ColombelJack Satsangi

Published in: Alimentary pharmacology & therapeutics (2020)

Although the majority of patients with IBD receive 5-ASA during their disease course, safe withdrawal appears possible in many, with important implications for both health economics and patient experience. A number of unanswered questions, however, remain.

Keyphrases

public health
healthcare
mental health
health information
health promotion
human health
risk assessment
social media